# Synthomer earnings and stock performance

> Live situation record from CLSTR: https://clstr.news/situations/synthomer-earnings-and-stock-performance
> Updated: 2026-08-04T10:03:47.000Z. Sources: 3. Developments: 2.

In mid‑July 2026, Synthomer plc’s shares broke above their 200‑day moving average, climbing to GBX 84.22 before closing at GBX 82. Analyst houses raised price targets, and insider Lily Liu bought a sizable block of shares. The same day, Spyre Therapeutics also saw a price jump after analyst upgrades, but the focus remained on Synthomer’s market momentum.

A few weeks later, Synthomer reported strong first‑half 2026 results, with revenue up 6.7% and EBITDA improving to a 10.1% margin. The company lifted its full‑year guidance, citing growth in specialty products, cost‑saving measures, and better cash generation. Management highlighted progress in intumescent coatings, sustainable CLIMA products, and medical adhesives, while noting temporary margin pressures at sites in the Netherlands and Texas. Pending divestments were expected to raise £150‑200 million, reinforcing the upbeat outlook.

## Timeline

### 2026-08-04: Context Therapeutics and Symbotic Miss Quarterly Earnings Expectations

Context Therapeutics posted a $0.05‑per‑share earnings miss, while Symbotic fell short by $0.04 per share despite revenue growth, as both Nasdaq firms reported quarterly results.

3 sources. https://clstr.news/cluster/synthomer-posts-strong-h1-2026-earnings-and-lifts-fullyear-outlook

### 2026-07-17: Synthomer and Spyre Therapeutics stocks rise above key moving averages amid analyst upgrades

Synthomer broke above its 200‑day average as analysts raised targets, while Spyre Therapeutics rose over 5% with analysts lifting price goals to $120‑$101.

2 sources. https://clstr.news/cluster/synthomer-and-spyre-therapeutics-stocks-rise-above-key-moving-averages-amid-analyst-upgrades

---
Cite as: Synthomer earnings and stock performance. CLSTR, https://clstr.news/situations/synthomer-earnings-and-stock-performance